Ecron Acunova Launches Direct Operation in Russia
GLOBAL
Ecron Acunova, a clinical research organization with offices across Europe, in India and the US, has strengthened its Eastern European presence further by opening a new office in Moscow, Russia in October 2009. Mrs Galyna Andriyko has been named as General Manager. She will lead the development of the Russian office operations.
“Russia has substantial unexplored capabilities. With its 141 million population and well recognized experience in clinical trials, Russia allows high recruitment rates, low drop-out rates and high quality data, to be obtained by dedicated medical professionals. With Mrs Andriyko’s expertise, we look forward to strengthening clinical trials in this region,” said Dr. Antal K. Hajos, Managing Director & CEO, Ecron Acunova, Europe said
Mrs Andriyko has successfully set up operations in Ukraine. The clinical team will be headed by Dr. Vlad Linievych, a physician, who has over 13 years of experience in industry. Ecron Acunova has been active in Russia for several years via collaborations and has 23 years of clinical expertise. Across Europe alone, Ecron Acunova covers 14 countries.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
June 24th 2025In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes, alongside notable improvements in glycemic control, supporting its advancement to Phase III studies as a potential once-monthly treatment option.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
